ArticleAnnals of hematology2026
Association of age and primary treatment with risk of non-lymphoma-related death and long-term survival outcomes in adult patients with early-stage follicular lymphoma: a population-based analysis.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
In adult patients with early-stage follicular lymphoma (FL), age-related differences in the risk of non-lymphoma-related death (LRD) during the follow-up period after treatment are unclear. We aimed to investigate the interactive effects of age and primary treatment on the risk of non-LRD and survival. We retrospectively analyzed the data of 6030 adult patients with early-stage FL from the Surveillance, Epidemiology, and End Results (SEER) database (2000-2020). Primary therapy involved observation (n = 2509), chemotherapy (CT) alone (n = 1844), radiotherapy alone (RT, n = 1191) or RT and CT (RT + CT, n = 486). The groups were balanced by inverse probability of treatment weighting (IPTW). Comparisons of the cumulative incidence of non-LRD were performed using competing-risk analysis and transformed Cox regression analysis. The median patient age was 64 years (RT, 62 years; RT + CT, 60 years; CT, 63 years; observation, 66 years). Over a median follow-up period of 132 months, 830 patients (13.8%) died of FL, while non-LRD accounted for 1279 patients (21.2%). Age significantly influenced the non-LRD risk, especially in patients aged > 60 years. After IPTW adjustment, RT alone, RT + CT or CT alone was not associated with an increased risk of the cumulative incidences of non-LRD or its specific causes in comparison with observation. Age-dependent analyses showed that the adjusted hazard ratios (HRs) for RT alone, RT + CT or CT versus observation remained close to 1.0 across the age spectrum, indicating no significant difference in non-LRD risk between treatment groups. RT alone and RT + CT conferred sustained overall survival (OS), disease specific survival (DSS) and relative survival (RS) advantages over CT or observation, with RS consistently exceeding 90% over the extended follow-up period. The survival benefit of RT versus non-RT persisted across age groups, with the adjusted HRs for OS and RS remaining below 1.0 for most ages. Older age, not primary treatment, was associated with an increased risk of non-LRD. The results indicated the safety and long-term survival benefit of RT in adult patients with early-stage FL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.